
News|Articles|December 1, 2006
Telbivudine
Telbivudine was approved on October 25, 2006, for the treatment of chronic hepatitis B virus (HBV) in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patient-facing EHR tool improves lung cancer screening identification
2
New therapies on the way to lower Lp(a), a cardiovascular risk factor
3
How California is rewriting the PBM playbook
4
Music-based sleep aids show the strongest evidence for improving sleep
5




















































